7don MSN
New generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancer
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...
New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer ...
Pfizer announces Tukysa combination significantly improves PFS as first-line maintenance in HER2+ metastatic breast cancer in HER2CLIMB-05 trial: New York Wednesday, October 15, 2 ...
News-Medical.Net on MSN
New antibody drug conjugates can transform early HER2-positive breast cancer treatment
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...
Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, ...
AstraZeneca and Amgen's TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately ...
Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...
A research team led by Prof. Ben Ko Chi-bun, Associate Professor of the PolyU Department of Applied Biology and Chemical Technology, has discovered the critical mechanism of action of tetrandrine, a ...
Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting ...
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback